News | EP Mapping and Imaging Systems | July 05, 2019

Innovative Health Receives FDA Clearance to Reprocess Pentaray Nav Eco High-density Mapping Catheter

Innovative Health developed new process to reprocess microlumen technology

Innovative Health Receives FDA Clearance to Reprocess Pentaray Nav Eco High-density Mapping Catheter

July 5, 2019 — Single-use cardiology medical device reprocessing company Innovative Health, received U.S. Food and Drug Administration (FDA) clearance for reprocessing the PentaRay Nav Eco High-Density mapping catheter manufactured by Biosense Webster. The PentaRay is a key medical device in atrial fibrillation (AF) procedures, one of the fastest growing and most expensive procedures in hospitals today, according to the company. Hospitals utilizing the reprocessed PentaRay and other expensive single-use labeled cardiology devices can save thousands of dollars on each AF procedure, potentially opening the procedure up for more patients.

The PentaRay catheter is an advanced technology whose capabilities include high-resolution mapping and coverage of all four chambers of the heart, which Biosense Webster associates with reduced procedure and fluoroscopy time. 

In the past, the device geometry provided a challenge for reprocessing and use a second time, because it contains microlumen technology (channels the size of a human hair), and an FDA clearance requires cleaning and testing access to all areas of the device. In this instance, Innovative Health collaborated with the FDA through the pre-submission process to seek their guidance on appropriate test methods for reprocessing this device. Through this interaction, Innovative Health created entirely new protocols and standards for reprocessing the device. This included state-of-the-art processes for removing blood and heparin out of the microlumen, and rigorous testing to ensure that these efforts were effective. Innovative Health’s own protocols also involved ensuring that the device was compatible with the entire Carto 3 mapping system, also manufactured by Biosense Webster, and that it meets specifications equivalent to the new device.

The new standards and processes used to reprocess the PentaRay will allow Innovative Health to reprocess other similar devices using microlumen technology, which is becoming dominant in AF ablation procedures.

Innovative Health CEO Rick Ferreira said that the FDA clearance to reprocess PentaRay will make it possible for hospitals to reduce AF ablation medical device costs by as much as 30 percent.

For more information: www.innovative-health.com

Related Content

PREDICT-AF trial showed first time there is extensive extracellular matrix remodeling. #HRS2020 #Heartrhythm2020. Marilyn Fornell
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Structural changes of the atrium may occur long before the onset of atrial fibrillation (AF), and the
Results of the Atrial Fibrosis Predicts Recurrent Stroke Or New Atrial Fibrillation In Patients With Embolic Stroke Of Undetermined Source - A Multi-Center Study at HRS 2020. #HRS2020 #Heartrhythm2020,
News | Atrial Fibrillation | May 19, 2020
May 19, 2020 — Atrial disease has been implicated in embolic stroke of undetermined source (ESUS) and a late-breaking
Contact Force Sensing Catheter Improved Outcomes in Persistent Atrial Fibrillation Ablation. #HRS2020 #heartrhythm2020
News | Atrial Fibrillation | May 13, 2020
May 13, 2020 — The PRECEPT study testing the use of the Biosense Webster Thermocool Smarttouch SF Catheter for the tr
The Swiss-AF study shows High Incidence Of Silent Brain Infarcts Found in Anticoagulated Atrial Fibrillation Patients. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 – A new clinical study found that patients with...
PINNACLE FLX Study of New Watchman FLX LAA Occluder Meets Safety and Efficacy Endpoints. #Heartrhythm2020 #HRS20 #HRS2020
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — Positive 12-month results were announced today from the...
The first-in-human results show positive results for Medtronic's pulsed field ablation in safety and efficiency. #Heartrhythm2020 #HRS2020 #HRS20
News | Atrial Fibrillation | May 08, 2020
May 8, 2020 — New clinical trial reveals the first-in-human results for paroxysmal or persistent atrial fibrillation
POPULAR TAVR trial Shows Oral Anticoagulants Alone in atrial fibrillation  (AF) Patients Reduces Bleeding Post TAVR, transcatheter aortic valve replacement. #ACC20 #ACC2020
News | Atrial Fibrillation | March 29, 2020
March 29, 2020 — Patients with atrial fibrillation (AF) who took oral anticoagulants alone after undergoing transcath
Medtronic's PulseSelect Pulsed Field Ablation (PFA) System

Medtronic's PulseSelect Pulsed Field Ablation (PFA) System.

News | Atrial Fibrillation | January 31, 2020
January 31, 2020 – The U.S.
Frequent Drinking Greater Risk Factor for Heart Rhythm Disorder Than Binge Drinking

Image courtesy of the American Heart Association.

News | Atrial Fibrillation | October 22, 2019
October 22, 2019 —  Drinking small amounts of alcohol frequently is linked with a higher likelihood of...